Patent Assignment
Reel/Frame 065178/0955
Release of Security Interest
Recorded: 2023-10-06
Pages: 10
Assignor
CITIBANK, N.A.
Executed: 2023-10-06
Assignee
HORIZON THERAPEUTICS U.S. HOLDING LLC (FKA RAPTOR PHARMACEUTICALS INC.)
1 HORIZON WAY, DEERFIELD, ILLINOIS, 60015
Covered Properties
(67)
Remedy for Cag Repeat Expansion Diseases
Patent:
6,355,690 →
Application:
09/236,002 →
Method and Compositions for Treating Diseases Mediated by Transglutaminase Activity
Patent:
6,794,414 →
Application:
09/719,770 →
Methods of Increasing Delivery of Active Agents to Brain Comprising Administering Receptor Associated Protein (Rap) Fragments Conjugated to Active Agents
Methods of Increasing Delivery of Active Agents to Brain Comprising Administering Receptor Associated Protein (Rap) Fragments Conjugated to Active Agents
Aerosolized Fluoroquinolones and Uses Thereof
Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for CR-Containing Proteins and Uses Thereof
Compositions Comprising Receptor-Associated Protein (Rap) Variants Specific for LRP2 and Uses Thereof
Compositions for Modulating Blood-Brain Barrier Transport
Treatment of Liver Disorders by Administration of Rap Conjugates
Receptor Associated Protein (Rap) Conjugates
Topical Use of Levofloxacin for Reducing Lung Inflammation
Aerosol Fluoroquinolone Formulations for Improved Pharmacokinetics
Cyclic Receptor-Associated Protein (Rap) Peptides
Aerosolized Fluoroquinolones and Uses Thereof
Aerosolized Fluoroquinolones and Uses Thereof
Aerosolized Fluoroquinolones and Uses Thereof
Compositions and Methods for Modulating Blood-Brain Barrier Transport
Aerosolized Fluoroquinolones and Uses Thereof
Protopanaxadiol-Type Ginsenoside Compositions and Uses Thereof
Megalin-Based Delivery of Therapeutic Compounds to the Brain and Other Tissues
Method for Treating Liver Disorders with Receptor Associated Protein (RAP) Peptide-Fucosidase Inhibitor Conjugates
Application:
13/016,135 →
Publication:
US 2011/0189084
Genotype Specific Methods for Treating Human Subjects Using 4-Methylpyrazole
Application:
13/376,933 →
Publication:
US 2012/0252857
Use of Aerosolized Levofloxacin for Treating Cystic Fibrosis
4-Methylpyrazole Formulations
Aerosolized Fluoroquinolones and Uses Thereof
Application:
14/012,307 →
Publication:
US 2014/0066441
Topical Use of Levofloxacin for Reducing Lung Inflammation
Application:
14/134,348 →
Publication:
US 2014/0105985
4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same
Methods for Analyzing Cysteamine Compositions
Aerosol Fluoroquinolone Formulations for Improved Pharmacokinetics
Use of Cysteamine and Derivatives Thereof to Treat Mitochondrial Diseases
Application:
14/534,887 →
Publication:
US 2015/0125526
Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for CR-Containing Proteins and Uses Thereof
Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same
4-Methylpyrazole Formulations
Application:
14/928,529 →
Publication:
US 2016/0151332
Methods of Treating Huntington's Disease Using Cysteamine Compositions
Application:
14/933,529 →
Publication:
US 2016/0128954
Host Defense Protein (HDP) Mimetics For Prophylaxis And/Or Treatment Of Inflammatory Diseases Of The Gastrointestinal Tract
Application:
15/042,923 →
Publication:
US 2016/0243117
Aerosol Fluoroquinolone Formulations for Improved Pharmacokinetics
4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
Application:
15/144,307 →
Publication:
US 2016/0243082
Aerosolized Fluoroquinolones and Uses Thereof
Application:
15/173,372 →
Publication:
US 2016/0279138
Ado-Resistant Cysteamine Analogs and Uses Thereof
Delayed Release Cysteamine Bead Formulation, and Methods of Making and Using Same
Application:
15/220,308 →
Publication:
US 2016/0331704
Fucosidase Inhibitors
Methods for Analyzing Cysteamine Compositions
Application:
15/229,777 →
Publication:
US 2016/0341706
Methods for Storing Cysteamine Formulations and Related Methods of Treatment
Genotype Specific Methods for Treating Human Subjects Using 4-Methylpyrazole
Application:
15/270,842 →
Publication:
US 2017/0007578
Compositions comprising receptor-associated protein (RAP) variants and uses thereof
Application:
60/690,480 →
Compositions comprising receptor-associated protein (RAP) variants and uses thereof
Application:
60/717,776 →
Compositions comprising receptor associated protein (RAP) variants selective for CR-containing proteins and uses thereof
Application:
60/813,954 →
Cyclic receptor-associated protein (RAP) peptides
Application:
60/919,238 →
Treatment of liver disorders by administration of receptor-associated protein (RAP)-conjugates
Application:
60/919,295 →
Protopanaxadiol-Type Ginsenoside Compositions and Uses Thereof
Application:
61/023,310 →
Genotype Specific Methods for Treating Human Subjects Using 4-Methylpyrazole
Application:
61/185,884 →
4-Methylpyrazole Formulations
Application:
61/267,389 →
Method for Treating Liver Tumors with Receptor Associated Protein (Rap) Peptide-Fucosidase Inhibitor Conjugates
Application:
61/299,177 →
Smooth, Spheroidal, Appendage Free Underwater Robot Capable of 5 Dof Motions
Application:
61/642,007 →
Delayed Release Cysteamine Bead Formulation
Application:
61/835,965 →
Methods for Analyzing Cysteamine Compositions
Application:
61/835,987 →
Use of Cysteamine and Derivatives Thereof to Treat Mitochondrial Diseases
Application:
61/900,772 →
Methods of Treating Huntington's Disease Using Cysteamine Compositions
Application:
62/075,536 →
ADO-Resistant Cysteamine Analogs and Uses Thereof
Application:
62/187,939 →
Fucosidase Inhibitors
Application:
62/199,194 →
Methods of Treating Non-Alcoholic Steatohepatitis (NASH) Using Cysteamine Compounds
Application:
62/256,035 →
Methods for Storing Cysteamine Formulations and Related Methods of Treatment
Application:
62/256,613 →
Fluoroquinolone Formulations for Cystic Fibrosis
Application:
62/292,065 →
Fluoroquinolone Formulations for Cystic Fibrosis
Application:
62/293,554 →
Fluoroquinolone Formulations for Cystic Fibrosis
Application:
62/348,439 →
ADO-resistant cysteamine analogs and uses thereof
Application:
62/387,337 →
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jan 22, 1999
From: TSUJI, SHOJI
To: NIIGATA UNIVERSITY
Reel/Frame 009732/0953 →
Assignment of Assignor's Interest
Sep 7, 2001
From: STEINMAN, LAWRENCE; KARPUJ, MARCELLA
To: YEDA RESEARCH AND DEVELOPMENT CO., LTD.
Reel/Frame 012143/0232 →
Assignment of Assignor's Interest
Sep 28, 2004
From: ZANKEL, TODD; STARR, CHRISTOPHER M.
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 015189/0949 →
Assignment of Assignor's Interest
May 22, 2006
From: BIOMARIN PHARMACEUTICAL INC.
To: RAPTOR PHARMACEUTICAL INC.
Reel/Frame 017912/0403 →
Assignment of Assignor's Interest
Aug 10, 2006
From: SURBER, MARK W.; BOSTIAN, KEITH A.; DUDLEY, MICHAEL N.; LOMOVSKAYA, OLGA
To: MPEX PHARMACEUTICALS, INC.
Reel/Frame 018097/0385 →
Assignment of Assignor's Interest
May 19, 2009
From: ZANKEL, TODD C.; STARR, CHRISTOPHER M.
To: RAPTOR PHARMACEUTICAL INC.
Reel/Frame 022709/0921 →
Assignment of Assignor's Interest
May 19, 2009
From: STARR, CHRISTOPHER M.; ZANKEL, TODD C.
To: RAPTOR PHARMACEUTICAL INC.
Reel/Frame 022717/0044 →
Assignment of Assignor's Interest
May 19, 2009
From: STARR, CHRISTOPHER M.; ZANKEL, TODD C.
To: RAPTOR PHARMACEUTICAL INC.
Reel/Frame 022709/0735 →
Assignment of Assignor's Interest
Dec 16, 2009
From: GRIFFITH, DAVID C.; DUDLEY, MICHAEL N.; SURBER, MARK W.; BOSTIAN, KEITH A.
To: MPEX PHARMACEUTICALS, INC.
Reel/Frame 023664/0233 →
Assignment of Assignor's Interest
Dec 16, 2009
From: DUDLEY, MICHAEL N.; TSIVKOVSKI, RUSLAN Y.; GRIFFITH, DAVID C.; RODNY, OLGA
To: MPEX PHARMACEUTICALS, INC.
Reel/Frame 023664/0215 →
Assignment of Assignor's Interest
Apr 16, 2012
From: SURBER, MARK W.; BOSTIAN, KEITH A.; DUDLEY, MICHAEL N.; LOMOVSKAYA, OLGA
To: MPEX PHARMACEUTICALS, INC.
Reel/Frame 028052/0773 →
Security Agreement
Dec 21, 2012
From: RAPTOR PHARMACEUTICAL CORP.; RAPTOR THERAPEUTICS INC.; RAPTOR DISCOVERIES INC.
To: HEALTHCARE ROYALTY PARTNERS II, L.P., AS LENDER
Reel/Frame 029531/0142 →
Assignment of Assignor's Interest
Feb 8, 2013
From: BIOMARIN PHARMACEUTICAL INC.
To: RAPTOR PHARMACEUTICAL INC.
Reel/Frame 029782/0714 →
Change of Name
Feb 8, 2013
From: RAPTOR PHARMACEUTICAL INC.
To: RAPTOR DISCOVERIES INC.
Reel/Frame 029782/0761 →
Merger
Feb 8, 2013
From: RAPTOR DISCOVERIES INC.
To: RAPTOR PHARMACEUTICAL INC.
Reel/Frame 029782/0795 →
Assignment of Assignor's Interest
Feb 8, 2013
From: BELIVEAU, RICHARD; DEMEULE, MICHEL; YANG, JOSEPH; KENNARD, MALCOLM L.
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 029783/0245 →
Assignment of Assignor's Interest
Feb 8, 2013
From: BIOMARIN PHARMACEUTICAL INC.
To: RAPTOR PHARMACEUTICAL INC.
Reel/Frame 029783/0294 →
Merger
Feb 8, 2013
From: RAPTOR DISCOVERIES INC.
To: RAPTOR PHARMACEUTICALS INC.
Reel/Frame 029783/0409 →
Assignment of Assignor's Interest
Feb 8, 2013
From: ZANKEL, TODD; STARR, CHRISTOPHER M.; GABATHULER, REINHARD
To: BIOMARIN PHARMACEUTICAL INC.
Reel/Frame 029783/0620 →
Change of Name
Feb 8, 2013
From: RAPTOR PHARMACEUTICAL INC.
To: RAPTOR DISCOVERIES INC.
Reel/Frame 029783/0506 →
Change of Name
Feb 8, 2013
From: RAPHOR PHARMACEUTICAL INC.
To: RAPTOR DISCOVERIES INC.
Reel/Frame 029778/0761 →
Merger
Feb 8, 2013
From: RAPTOR DISCOVERIES INC.
To: RAPTOR PHARMACEUTICALS INC.
Reel/Frame 029778/0794 →
Change of Name
Feb 8, 2013
From: RAPTOR PHARMACEUTICAL INC.
To: RAPTOR DISCOVERIES INC.
Reel/Frame 029778/0885 →
Merger
Feb 8, 2013
From: RAPTOR DISCOVERIES INC.
To: RAPTOR PHARMACEUTICALS INC.
Reel/Frame 029778/0921 →
Change of Name
Feb 8, 2013
From: RAPTOR PHARMACEUTICAL INC.
To: RAPTOR DISCOVERIES INC.
Reel/Frame 029779/0037 →